Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab.

导出 LinkOut

翻译打印收藏纠错

第一作者： Vincent T,Ma

第一单位： Department of Internal Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin, Madison, WI, United States.

作者： Vincent T,Ma ^[1] ; Alahendra A,Chamila Perera ^[2] ; Yilun,Sun ^[3] ; Merna,Sitto ^[3] ; Jessica J,Waninger ^[4] ; Govind,Warrier ^[5] ; Michael D,Green ^[4] ; Leslie A,Fecher ^[5] ; Christopher D,Lao ^[6]

作者单位： Department of Internal Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin, Madison, WI, United States. ^[1] Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States. ^[2] Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States. ^[3] Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States. ^[4] Department of Medical Education, University of Michigan, Ann Arbor, MI, United States. ^[5] Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. ^[6] Department of Radiation Oncology, Veteran Affairs Ann Arbor Hospital System, Ann Arbor, MI, United States. ^[7]

关键词 biomarker combination immune checkpoint therapy early response assessment immune related adverse effects ipilimumab and nivolumab melanoma radiological assessment

主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);人类(Humans);黑色素瘤(Melanoma);回顾性研究(Retrospective Studies)

DOI 10.3389/fimmu.2022.860421

PMID 35874737

发布时间 2022-10-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交